Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
UKV91nZu0GFZ9Y4e